Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers

Bibliography

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917
   PubMed Web of Science ®Google Scholar
• Cunningham D, Starling N, Rao S, Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46
   PubMed Web of Science ®Google Scholar
• Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-91
   PubMed Web of Science ®Google Scholar
• Glimelius B, Ekstrom K, Hoffman K, Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-8
   PubMed Web of Science ®Google Scholar
• Wagner AD, Unverzagt S, Grothe W, Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010;CD004064
   Google Scholar
• Perz JF, Armstrong GL, Farrington LA, The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-38
   PubMed Web of Science ®Google Scholar
• El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 2007;37(Suppl 2):S88-94
   PubMed Web of Science ®Google Scholar
• Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-91
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Global cancer statistics. CA Cancer J Clin 2011;61:69-90
   PubMed Web of Science ®Google Scholar
• Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37(Suppl 4):S3-8
   PubMed Web of Science ®Google Scholar
• Perez-Soler R. HER1/EGFR targeting: refining the strategy. Oncologist 2004;9:58-67
   PubMed Web of Science ®Google Scholar
• Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232
   PubMed Web of Science ®Google Scholar
• Burgess AW, Cho HS, Eigenbrot C, An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003;12:541-52
   PubMed Web of Science ®Google Scholar
• Cohen S, Carpenter G, King L Jr. Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J Biol Chem 1980;255:4834-42
   PubMed Web of Science ®Google Scholar
• Normanno N, De Luca A, Bianco C, Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2-16
   PubMed Web of Science ®Google Scholar
• Hanawa M, Suzuki S, Dobashi Y, EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 2006;118:1173-80
   PubMed Web of Science ®Google Scholar
• Itakura Y, Sasano H, Shiga C, Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer 1994;74:795-804
   PubMed Web of Science ®Google Scholar
• Wang KL, Wu TT, Choi IS, Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 2007;109:658-67
   PubMed Web of Science ®Google Scholar
• Kim MA, Lee HS, Lee HE, EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 2008;52:738-46
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6
   PubMed Web of Science ®Google Scholar
• Ito Y, Takeda T, Sakon M, Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer 2001;84:1377-83
   PubMed Web of Science ®Google Scholar
• McKay JA, Murray LJ, Curran S, Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 2002;38:2258-64
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45
   PubMed Web of Science ®Google Scholar
• Galizia G, Lieto E, De Vita F, Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene 2007;26:3654-60
   PubMed Web of Science ®Google Scholar
• Baselga J, Pfister D, Cooper MR, Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18:904-14
   PubMed Web of Science ®Google Scholar
• Okines A, Cunningham D, Chau I. Targeting the human EGFR family in esophagogastric cancer. Nat Rev Clin Oncol 2011;8:492-503
   PubMed Web of Science ®Google Scholar
• Reddy D, Wainberg ZA. Targeted therapies for metastatic esophagogastric cancer. Curr Treat Options Oncol 2011;12:46-60
   PubMed Web of Science ®Google Scholar
• Enzinger PC, Burtness B, Hollis D, CALGB 80403/ECOG 1206: a randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. J Clin Oncol 2010;28:15s
   PubMed Web of Science ®Google Scholar
• Lorenzen S, Schuster T, Porschen R, Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2009;20:1667-73
   PubMed Web of Science ®Google Scholar
• Asnacios A, Fartoux L, Romano O, Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer 2008;112:2733-9
   PubMed Web of Science ®Google Scholar
• Xiong HQ, Rosenberg A, LoBuglio A, Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 2004;22:2610-16
   PubMed Web of Science ®Google Scholar
• Philip PA, Benedetti J, Corless CL, Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010;28:3605-10
   PubMed Web of Science ®Google Scholar
• Louafi S, Boige V, Ducreux M, Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 2007;109:1384-90
   PubMed Web of Science ®Google Scholar
• Sanoff HK, Bernard S, Goldberg RM, Phase II study of Capecitabine, Oxaliplatin, and Cetuximab for advanced hepatocellular carcinoma. Gastrointest Cancer Res 2011;4:78-83
   PubMedGoogle Scholar
• Van Cutsem E, Kohne CH, Hitre E, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Bondarenko I, Makhson A, Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-71
   PubMed Web of Science ®Google Scholar
• Berardi R, Onofri A, Pistelli M, Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer. Core Evid 2010;5:61-76
   PubMedGoogle Scholar
• Okines AF, Ashley SE, Cunningham D, Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J Clin Oncol 2010;28:3945-50
   PubMed Web of Science ®Google Scholar
• Waddelll TS, Chau I, Brarbachano Y, A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3). J Clin Oncol 2012;30(Suppl)):abstract LBA40000
   Google Scholar
• Kim GP, Foster NR, Salim M, Randomized phase II trial of panitumumab, erlotinib, and gemcitabine (PGE) versus erlotinib-gemcitabine (GE) in patients with untreated, metastatic pancreatic adenocarcinoma. J Clin Oncol 2011;29(Suppl):abstract 4030
   Google Scholar
• Sun W, Mykulowycz K, Teitelbaum UR, Panitumumab, gemcitabine, and irinotecan in patients with advanced or metastatic cholangiocarcinoma: a phase II study. J Clin Oncol 2010;28(Suppl):abstract TPS214
   Google Scholar
• Van Cutsem E, Peeters M, Siena S, Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-64
   PubMed Web of Science ®Google Scholar
• Hecht JR, Mitchell E, Chidiac T, A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009;27:672-80
   PubMed Web of Science ®Google Scholar
• Douillard JY, Siena S, Cassidy J, Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28:4697-705
   PubMed Web of Science ®Google Scholar
• Vanhoefer U, Tewes M, Rojo F, Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 2004;22:175-84
   PubMed Web of Science ®Google Scholar
• Rao S, Starling N, Cunningham D, Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Ann Oncol 2010;21:2213-19
   PubMed Web of Science ®Google Scholar
• Dragovich T, McCoy S, Fenoglio-Preiser CM, Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006;24:4922-7
   PubMed Web of Science ®Google Scholar
• Wainberg ZA, Lin LS, DiCarlo B, Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. Br J Cancer 2011;105:760-5
   PubMed Web of Science ®Google Scholar
• Thomas MB, Chadha R, Glover K, Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007;110:1059-67
   PubMed Web of Science ®Google Scholar
• Chiorean EG, Ramasubbaiah R, Yu M, Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: hoosier Oncology Group GI06-101. Oncologist 2012;17:13
   PubMed Web of Science ®Google Scholar
• Philip PA, Mahoney MR, Holen KD, Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer. Cancer 2012;118:2424-30
   PubMed Web of Science ®Google Scholar
• Kozuch P, Malamud S, Wasserman C, Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer. Clin Colorectal Cancer 2009;8:38-42
   PubMed Web of Science ®Google Scholar
• Messersmith WA, Jimeno A, Jacene H, Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. Clin Colorectal Cancer 2010;9:297-304
   PubMed Web of Science ®Google Scholar
• Meyerhardt JA, Stuart K, Fuchs CS, Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. Ann Oncol 2007;18:1185-9
   PubMed Web of Science ®Google Scholar
• Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006;24:1612-19
   PubMed Web of Science ®Google Scholar
• Ferry DR, Anderson M, Beddard K, A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res 2007;13:5869-75
   PubMed Web of Science ®Google Scholar
• Ferry DR. Phase III multi-centre, randomised, double-blind, placebo-controlled parallel arm of geftinib versus placebo in esophgeal cancer progressing after chemotherapy on behalf of the COG (Cancer Oesophagus Gefitinib) Collaborative Group [abstract LBA20_PR]. European Society of Medical Oncology (ESMO) 2012 Congress; Vienna, Austria; 2012
   Google Scholar
• Doi T, Koizumi W, Siena S, Efficacy, tolerability and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer. Proc Am Soc Clin Oncol 2003;22:abstract 1036
   Google Scholar
• Phase II Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma. Available from: ClinicalTrials.gov, http://clinicaltrials.gov/show/NCT00177242 [Accessed 4 October 2012]
   Google Scholar
• O'Dwyer PJ, Giantonio BJ, Levy DE, Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern cooperative oncology group's study E1203. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24:abstract No. 4143
   Web of Science ®Google Scholar
• Rothenberg ML, LaFleur B, Levy DE, Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. J Clin Oncol 2005;23:9265-74
   PubMed Web of Science ®Google Scholar
• Fukushige S, Matsubara K, Yoshida M, Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol 1986;6:955-8
   PubMed Web of Science ®Google Scholar
• Rowinsky EK. Signal events: cell signal transduction and its inhibition in cancer. Oncologist 2003;8(Suppl 3):5-17
   PubMed Web of Science ®Google Scholar
• Kraus AC, Ferber I, Bachmann SO, In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways. Oncogene 2002;21:8683-95
   PubMed Web of Science ®Google Scholar
• Sakai K, Mori S, Kawamoto T, Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Natl Cancer Inst 1986;77:1047-52
   PubMed Web of Science ®Google Scholar
• Ooi A, Takehana T, Li X, Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 2004;17:895-904
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97
   PubMed Web of Science ®Google Scholar
• Xian ZH, Zhang SH, Cong WM, Overexpression/amplification of HER-2/neu is uncommon in hepatocellular carcinoma. J Clin Pathol 2005;58:500-3
   PubMed Web of Science ®Google Scholar
• Zender L, Villanueva A, Tovar V, Cancer gene discovery in hepatocellular carcinoma. J Hepatol 2010;52:921-9
   PubMed Web of Science ®Google Scholar
• Safran H, Steinhoff M, Mangray S, Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol 2001;24:496-9
   PubMed Web of Science ®Google Scholar
• Harder J, Ihorst G, Heinemann V, Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. Br J Cancer 2012;106:1033-8
   PubMed Web of Science ®Google Scholar
• Safran H, Iannitti D, Ramanathan R, Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest 2004;22:706-12
   PubMed Web of Science ®Google Scholar
• Cartwright TH, Cohn A, Varkey JA, Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002;20:160-4
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Hwang JJ, Zamboni WC, Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest 2004;22:858-65
   PubMed Web of Science ®Google Scholar
• Blackwell KL, Miles D, Gianni L, Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. J Clin Oncol 2012;30(Suppl):abstract LBA1
   Google Scholar
• A randomized, multicenter, adaptive phase II/III study to evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) versus taxane (Docetaxel Or Paclitaxel) in patients with previously treated locally advanced or metastatic Her2-positive gastric cancer, including adenocarcinoma of the gastroesophageal junction. Available from: http://clinicaltrials.gov/ct2/show/NCT01641939 [Accessed 6 October 2012]
   Google Scholar
• Baselga J, Cortes J, Kim SB, Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109-19
   PubMed Web of Science ®Google Scholar
• Keating GM. Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer. Drugs 2012;72:353-60
   PubMed Web of Science ®Google Scholar
• Yamashita-Kashima Y, Iijima S, Yorozu K, Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin Cancer Res 2011;17:5060-70
   PubMed Web of Science ®Google Scholar
• Agus DB, Gordon MS, Taylor C, Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005;23:2534-43
   PubMed Web of Science ®Google Scholar
• Phase II study of pertuzumab and erlotinib for refractory pancreatic adenocarcinoma. Available from: Clinicaltrials.gov, http://clinicaltrials.gov/ct2/show/NCT01108458 [Accessed 30 November 2012]
   Google Scholar
• A study of pertuzumab in combination with trastuzumab and chemotherapy in patients with HER2-positive advanced gastric cancer. Available from: ClinicalTrials.gov, http://clinicaltrials.gov/ct2/show/NCT01461057 [Accessed 6 October 2012]
   Google Scholar
• A phase I/II trial of pertuzumab in combination with cetuximab in cetuximab-refractory metastatic colorectal cancer. Available from: ClinicalTrials.gov, http://clinicaltrials.gov/ct2/show/NCT00551421 [Accessed 6 October 2012]
   Google Scholar
• mFOLFIRI combine with nimotuzumab second line chemotherapy for squamous-cell carcinoma of the Esophagus. Available from: Clinicaltrials.gov, http://clinicaltrials.gov/ct2/show/results/NCT01486992?term=NCT01486992&rank=1 [Accessed 6 October 2012]
   Google Scholar
• Nimotuzumab in combination with chemoradiation for local advanced esophageal squamous cell carcinoma. Available from: ClinicalTrials.gov, http://clinicaltrials.gov/ct2/show/NCT01232374 [Accessed 6 October 2012]
   Google Scholar
• Combination of nimotuzumab, capecitabine and radiotherapy for inoperable or recurrent gastric cancer. Available from: ClinicalTrials.gov, http://clinicaltrials.gov/show/NCT01180166 [Accessed 6 October 2012]
   Google Scholar
• Nimotuzumab in adults with pancreatic cancer. Available from: Clinicaltrials.gov, http://www.clinicaltrials.gov/ct2/show/NCT00561990 [Accessed 6 October 2012]
   Google Scholar
• Strumberg D, Schultheis B, Scheulen ME, Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Invest New Drugs 2012;30:1138-43
   PubMed Web of Science ®Google Scholar
• Open label, dose escalating study with ertumaxomab in patients with HER-2/Neu expressing advanced solid tumors. Available from: Clinicaltrials.gov, http://clinicaltrials.gov/ct2/show/NCT01569412 [Accessed 6 October 2012]
   Google Scholar
• Geyer CE, Forster J, Lindquist D, Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43
   PubMed Web of Science ®Google Scholar
• Wainberg ZA, Anghel A, Desai AJ, Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res 2010;16:1509-19
   PubMed Web of Science ®Google Scholar
• Roth A, Moehler MH, Mauer M, Lapatinib in combination with ECF/x in EGFR1 or HER2-overexpressing first-line metastatic gastric cancer (GC): a phase II randomized placebo controlled trial (EORTC 40071). J Clin Oncol 2010;28(Suppl):abstract TPS205
   Google Scholar
• Satoh T, Bang Y, Wang J, Interim safety analysis from TYTAN: A phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancer. J Clin Oncol 2010;28(Suppl):abstract 4057
   Google Scholar
• A Phase III study for ErbB2 positive advanced or metastatic gastric, esophageal, or gastroesophageal junction adenocarcinoma treated with capecitabine plus oxaliplatin with or without lapatinib. Available from: Clinicaltrials.gov, http://clinicaltrials.gov/ct2/show/NCT00680901 [ [Accessed 7 October 2012]
   Google Scholar
• Singla S, Pippin JA, Drebin JA. Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer. Oncol Rep 2012;28(6):2211-16
   PubMed Web of Science ®Google Scholar
• Safran H, Miner T, Bahary N, Lapatinib and gemcitabine for metastatic pancreatic cancer: a phase II study. J Clin Oncol 2009;27:e15653
   Google Scholar
• Frank D, Jumonville A, Loconte NK, A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma: a Wisconsin Oncology Network study. J Gastrointest Oncol 2012;3:90-6
   PubMedGoogle Scholar
• A phase II study of Afatinib (BIBW 2992) in patients with advanced HER2-positive Trastuzumab-refractory advanced Esophagogastric cancer. Available from: ClinicalTrials.gov, http://clinicaltrials.gov/ct2/show/NCT01522768 [Accessed 7 October 2012]
   Google Scholar
• An open label, partially randomised phase II study to investigate the efficacy and safety of BIBW 2992 in patients with metastatic colorectal cancer who never received prior anti-EGFR (Epidermal Growth Factor Receptor) treatment. Available from: ClinicalTrials.gov, http://clinicaltrials.gov/ct2/show/NCT01152437 [Accessed 7 October 2012]
   Google Scholar
• Ioannou N, Dalgleish AG, Seddon AM, Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. Br J Cancer 2011;105:1554-62
   PubMed Web of Science ®Google Scholar
• Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 2007;97:453-7
   PubMed Web of Science ®Google Scholar
• Soltoff SP, Carraway KL III, Prigent SA, ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 1994;14:3550-8
   PubMed Web of Science ®Google Scholar
• Reschke M, Mihic-Probst D, van der Horst EH, HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res 2008;14:5188-97
   PubMed Web of Science ®Google Scholar
• Beji A, Horst D, Engel J, Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer. Clin Cancer Res 2012;18:956-68
   PubMed Web of Science ®Google Scholar
• Amin DN, Campbell MR, Moasser MM. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol 2010;21:944-50
   PubMed Web of Science ®Google Scholar
• Garrett JT, Olivares MG, Rinehart C, Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci USA 2011;108:5021-6
   PubMedGoogle Scholar
• Berlin J, Keedy VL, Janne PA, A first-in-human phase I study of U3-1287 (AMG 888), a HER3 inhibitor, in patients (pts) with advanced solid tumors. J Clin Oncol 2011;29(Suppl):abstract 3026
   Google Scholar
• Schoeberl B, Faber AC, Li D, An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res 2010;70:2485-94
   PubMed Web of Science ®Google Scholar
• Sequist LV, Harb WA, Modiano M, A phase I/II trial of MM-121 in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol 2011;29(Suppl):abstract TPS215
   Google Scholar
• A Phase 1 study of MM-121 in combination with cetuximab and irinotecan in patients with advanced cancers. Available from: ClinicalTrials.gov, http://clinicaltrials.gov/ct2/show/NCT01451632 [Accessed 8 October 2012]
   Google Scholar
• Kamath AV, Lu D, Gupta P, Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose. Cancer Chemother Pharmacol 2012;69:1063-9
   PubMed Web of Science ®Google Scholar
• Nam HJ, Ching KA, Kan J, Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer. Mol Cancer Ther 2012;11:439-51
   PubMed Web of Science ®Google Scholar
• Oh DY, Lee KW, Cho JY, A phase II open-label trial of dacomitinib monotherapy in patients with HER2-positive advanced gastric cancer after failure of at least one prior chemotherapy regimen. J Clin Oncol 2012;30(Suppl 4):abstract 54
   Google Scholar
• Dechant M, Weisner W, Berger S, Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res 2008;68:4998-5003
   PubMed Web of Science ®Google Scholar
• Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000;60:1383-7
   PubMed Web of Science ®Google Scholar
• Hopper-Borge EA, Nasto RE, Ratushny V, Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin Ther Targets 2009;13:339-62
   PubMed Web of Science ®Google Scholar
• Castillo J, Erroba E, Perugorria MJ, Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res 2006;66:6129-38
   PubMed Web of Science ®Google Scholar
• Mimura K, Kono K, Hanawa M, Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer 2005;92:1253-60
   PubMed Web of Science ®Google Scholar
• Wei Q, Chen L, Sheng L, EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol 2007;31:493-9
   PubMed Web of Science ®Google Scholar
• Xu S, Kitayama J, Yamashita H, Nuclear translocation of HER-4/c-erbB-4 is significantly correlated with prognosis of esophageal squamous cell carcinoma. J Surg Oncol 2008;97:44-50
   PubMed Web of Science ®Google Scholar
• Reichelt U, Duesedau P, Tsourlakis M, Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 2007;20:120-9
   PubMed Web of Science ®Google Scholar
• Begnami MD, Fukuda E, Fregnani JH, Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol 2011;29:3030-6
   PubMed Web of Science ®Google Scholar
• Tanner M, Hollmen M, Junttila TT, Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005;16:273-8
   PubMed Web of Science ®Google Scholar
• Tobita K, Kijima H, Dowaki S, Epidermal growth factor receptor expression in human pancreatic cancer: significance for liver metastasis. Int J Mol Med 2003;11:305-9
   PubMed Web of Science ®Google Scholar
• Hirakawa T, Nakata B, Amano R, HER3 overexpression as an independent indicator of poor prognosis for patients with curatively resected pancreatic cancer. Oncology 2011;81:192-8
   PubMed Web of Science ®Google Scholar
• Kountourakis P, Pavlakis K, Psyrri A, Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer 2006;6:46
   PubMed Web of Science ®Google Scholar